Selux is on a mission to outsmart bacteria

With rapid Phenotypic AST

A Selux worker in the lab

Changing the status quo

Antibiotic susceptibility testing (AST) hasn’t seen true innovation in over 20+ years. All the while, bacteria have been evolving faster than science, creating resistance to lifesaving antibiotics.

According to the World Health Organization, antibiotic resistance is rising to dangerously high levels, becoming the next global health crisis. Selux is on a mission to combat superbugs and preserve the lifesaving power of antibiotics for future generations.

Selux 3 Instrument Suite

The global health crisis of antimicrobial resistant infections is a complex and multidimensional problem. One solution is the science and technology of Selux.

To preserve the lifesaving power of antibiotics we need faster diagnostic results, susceptibility testing on all sample types, testing against all commercially relevant antibiotics at one time, and a commitment to updated breakpoints.

Learn how Selux can help

A patient in a hospital bed

Redefining patient care and antibiotic stewardship with rapid AST

Despite the importance of antimicrobial susceptibility testing (AST) to infectious diseases patient care, current AST systems either limit result speed, accuracy, or consistency. This forces an overreliance on broad-spectrum antibiotics and contributes to antimicrobial resistance. While multiple rapid AST technologies are under development, these are restricted to bloodstream infections so they cannot address the vast majority of hospitalized patients with other infections. The Selux NGP System offers same shift results, direct from positive blood culture and isolates.



Of antibiotics used in hospitals are either unnecessary or are prescribed incorrectly.

Selux Diagnostics


Every 15 minutes someone new dies of an antibiotic-resistant infection.

Super bug


The year by which superbugs are expected to surpass cancer as a leading cause of death.

Let’s outsmart bacteria together.

Stay up to date with the latest breakpoint and the clinical impact of AST reporting.